Orchestra BioMed Holdings, Inc.OBIOEarnings & Financial Report
Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.
Revenue
$778.0K
Gross Profit
$734.0K
Operating Profit
$-16.9M
Net Profit
$-16.0M
Gross Margin
94.3%
Operating Margin
-2167.0%
Net Margin
-2054.0%
YoY Growth
-15.0%
EPS
$-0.45
Financial Flow
Orchestra BioMed Holdings, Inc. Q2 2024 Financial Summary
Orchestra BioMed Holdings, Inc. reported revenue of $778.0K (down 15.0% YoY) for Q2 2024, with a net profit of $-16.0M (down 32.7% YoY) (-2054.0% margin). Cost of goods sold was $44.0K, operating expenses totaled $17.6M.
Key Financial Metrics
| Total Revenue | $778.0K |
|---|---|
| Net Profit | $-16.0M |
| Gross Margin | 94.3% |
| Operating Margin | -2167.0% |
| Report Period | Q2 2024 |
Orchestra BioMed Holdings, Inc. Annual Revenue by Year
Orchestra BioMed Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $33.5M |
| 2024 | $2.6M |
| 2023 | $2.8M |
| 2022 | $3.5M |
Orchestra BioMed Holdings, Inc. Quarterly Revenue & Net Profit History
Orchestra BioMed Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $30.9M | +12120.2% | $6.2M | 20.2% |
| Q3 2025 | $861.0K | -12.8% | $-20.8M | -2419.0% |
| Q2 2025 | $836.0K | +7.5% | $-19.4M | -2316.1% |
| Q1 2025 | $868.0K | +40.0% | $-18.8M | -2160.7% |
| Q4 2024 | $253.0K | -3.4% | $-16.2M | -6385.4% |
| Q3 2024 | $987.0K | +135.6% | $-15.4M | -1562.9% |
| Q2 2024 | $778.0K | -15.0% | $-16.0M | -2054.0% |
| Q1 2024 | $620.0K | -46.7% | $-13.5M | -2171.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $620000 | $778000 | $987000 | $253000 | $868000 | $836000 | $861000 | $30.9M |
| YoY Growth | -46.7% | -15.0% | 135.6% | -3.4% | 40.0% | 7.5% | -12.8% | 12120.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $82.6M | $72.4M | $75.3M | $76.2M | $59.1M | $42.8M | $104.8M | $114.9M |
| Liabilities | $25.4M | $28.3M | $29.1M | $43.2M | $42.2M | $42.5M | $61.1M | $51.5M |
| Equity | $57.2M | $44.1M | $46.2M | $33.0M | $16.9M | $295000 | $43.7M | $53.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-13.1M | $-10.2M | $-13.7M | $-13.5M | $-16.6M | $-15.5M | $-14.6M | $-2.3M |